Pharma Industry Decision Quality ROI

Click to enlarge
-
During the seven years of portfolio DA adoption across the Pharmaceutical Industry, we tracked the Adopters Index against the DJ Pharma Index and the much broader S&P 500 Index.
"In the end we learned that our portfolio was worth $2.6 billion more than it was when we started. This was powerful confirmation that our efforts were worthwhile."
- – Paul Sharpe, VP SmithKline Beecham
(now GlaxoSmithkline)
"I estimate the extra cost to SB for this effort was $2 Million.
So the payoff was 1300 to 1.
"